Immutep receives A$686,704 R&D Tax Incentive
Filed with ASX · · 1 page · English
Story so far
Earlier from Immutep
- Outcome of DSMB Safety Review & Extension of TACTI-mel
- Immutep receives USD1M milestone payment from EOC
- European patent grant for IMP321 in cancer
- Japanese Patent Grant for IMP731 Antibody
- Japanese Patent Grants For IMP321 In Infectious Disease
Later from Immutep
- US patent grant for IMP701 antibody
- Immutep raises A$6.85M through institutional placement
- Response to ASX Price Query
- Webcast slides for TACTI-mel clinical trial data
- Mid-point of patient enrolment reached in AIPAC trial
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep